The high cost of translating therapeutic discoveries into clinically available agents can deter the development of promising therapies. Researchers may partner with private-sector entities to advance projects with significant commercial potential, but high-risk ideas or therapies for uncommon disorders frequently do not attract investors.
When private-sector resources are limited, BrIDGs research and development expertise and services can help researchers bridge the gap between the preclinical and clinical stages of therapeutic development. This support enables continued evaluation of agents that may improve the standard of care for patients with a variety of diseases and disorders.